Literature DB >> 9886527

Ovarian hyperstimulation following the sole administration of agonistic analogues of gonadotrophin releasing hormone.

A Weissman1, A Barash, H Shapiro, R F Casper.   

Abstract

Ovarian hyperstimulation following the sole administration of gonadotrophin-releasing hormone agonists (GnRHa) is exceedingly rare. We hereby report on two infertile patients undergoing in-vitro fertilization-embryo transfer who developed ovarian hyperstimulation under such circumstances. In both patients, GnRHa were administered using the 'long protocol' regimen. The first patient developed ovarian hyperstimulation on two occasions, with mid-luteal depot administration of triptorelin and with early follicular triptorelin, administered as daily subcutaneous injections. In both cycles, within 2 weeks of triptorelin therapy, massive ovarian multifollicular enlargement occurred, concomitant with high serum oestradiol concentrations, which resolved spontaneously following expectant management. The second patient developed ovarian hyperstimulation following daily injections of leuprolide acetate starting at the mid-luteal phase. The final stage of ovulation was triggered by human chorionic gonadotrophin (HCG) and 11 oocytes were retrieved. In-vitro fertilization resulted in embryo formation, but failed to result in pregnancy. The same phenomenon recurred in a subsequent cycle despite preventive pretreatment with an oral contraceptive. A negative GnRH test, performed just before HCG administration, suggested than an ongoing 'flare-up effect' was unlikely to cause ovarian stimulation. Ovarian hyperstimulation can occur following the sole administration of GnRHa irrespective of the preparation used and the administration protocol. Although spontaneous resolution is the rule, once this condition has developed, HCG administration and oocyte retrieval are feasible. This rare entity probably represents an exaggerated form of ovarian cyst formation following GnRHa administration, the underlying pathophysiology of which remains unresolved.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9886527     DOI: 10.1093/humrep/13.12.3421

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  6 in total

1.  Ovarian hyperstimulation after the sole use of a gonadotrophin-releasing hormone agonist (Nafarelin) as a complication of in vitro fertilisation treatment.

Authors:  S Brett; P Y Yong; K J Thong
Journal:  J Assist Reprod Genet       Date:  2001-06       Impact factor: 3.412

2.  Ovarian hyper-response to administration of an GnRH-agonist without gonadotropins.

Authors:  Hyun Tae Park; Hyo Sook Bae; Tak Kim; Sun Haeng Kim
Journal:  J Korean Med Sci       Date:  2011-10-01       Impact factor: 2.153

3.  HCG Trigger of GnRH Agonist-Induced Functional Ovarian Cysts Does Not Decrease Clinical Pregnancy Rate in GnRHa Pretreated Frozen Cycles: Evidence From a Retrospective Cohort Study.

Authors:  Hong Zeng; Chen Zhang; Lei Zhang; Nenghui Liu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-15       Impact factor: 6.055

Review 4.  Progress in understanding human ovarian folliculogenesis and its implications in assisted reproduction.

Authors:  Dong Zi Yang; Wan Yang; Yu Li; Zuanyu He
Journal:  J Assist Reprod Genet       Date:  2013-02       Impact factor: 3.412

5.  Severe ovarian hyperstimulation syndrome associated with long-acting GnRH agonist in oncofertility patients.

Authors:  Jacob Christ; Christopher N Herndon; Bo Yu
Journal:  J Assist Reprod Genet       Date:  2021-01-20       Impact factor: 3.412

6.  Evaluation of granulocyte colony-stimulating factor effects on treatment-resistant thin endometrium in women undergoing in vitro fertilization.

Authors:  Michał Kunicki; Krzysztof Łukaszuk; Izabela Woclawek-Potocka; Joanna Liss; Patrycja Kulwikowska; Joanna Szczyptańska
Journal:  Biomed Res Int       Date:  2014-02-12       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.